Study of prognosis in adults with acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how acute myeloid leukemia behaves over time in adults and may help doctors better predict outcomes. You might be eligible if you have AML and agree to take part in research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have a diagnosis of acute myeloid leukemia (AML)
- Agree to take part in medical research
- Do not have acute promyelocytic leukemia (a specific AML subtype)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This registry collects information from adults with AML diagnosed since 2020. It helps doctors understand and improve treatment for this blood cancer.
This study uses a geriatric assessment to choose the best treatment for people aged 60 and older with acute myeloid leukemia (AML). The goal is to tailor therapy based on your overall health and function.
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.